Advanced NSCLC: what are the options?

An independent satellite symposium held in conjunction with the 17th European Congress: Perspectives in Lung Cancer. Prague, Czech Republic

Congress Hall I & II
Friday 4 March 2016, 11:40-13:10

Chaired by Giorgio Scagliotti and Pieter Postmus

- Biopsy to guide personalised treatment
- Optimal treatment for the specific patient: case studies
- Current and future best practice for individualised care

This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company
Contents

3 Programme & Learning objectives

4 Welcome message

5 Chair biographies
Giorgio Scagliotti and Pieter Postmus

6 Faculty biographies
Silvia Novello, Fabrice Barlesi, Erik Thunnissen

7 Symposium information
Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40–11:45</td>
<td>Welcome and introduction</td>
<td>Pieter Postmus (UK)</td>
</tr>
<tr>
<td>11:45–12:00</td>
<td>Biopsy to guide personalised treatment</td>
<td>Erik Thunnissen (Netherlands)</td>
</tr>
<tr>
<td>12:00–12:40</td>
<td>Optimal treatment for the specific patient: case studies</td>
<td>Silvia Novello (Italy) Fabrice Barlesi (France)</td>
</tr>
<tr>
<td>12:40–13:05</td>
<td>Current and future best practice for individualised care</td>
<td>All Faculty</td>
</tr>
<tr>
<td>13:05–13:10</td>
<td>Closing remarks</td>
<td>Giorgio Scagliotti (Italy)</td>
</tr>
</tbody>
</table>

Learning objectives

Following attendance at this symposium delegates are expected to:

- Understand how best to use re-biopsy and liquid biopsy to guide therapy for advanced and metastatic NSCLC
- Understand and demonstrate knowledge on how to best use the rapidly expanding and complex range of treatment options for the individual patient with advanced and metastatic NSCLC
- Understand the emerging therapies for advanced and metastatic NSCLC and the future treatment paradigms they create
Welcome message

Dear colleagues

Welcome to Prague, the ‘City of Spires’, and thank you for attending this satellite symposium ‘Advanced NSCLC: what are the options?’ at the Perspectives in Lung Cancer (PILC) congress. We hope you will find it engaging and informative.

PILC provides a unique environment for a focused dialogue among experts in lung cancer. It is within this environment that we will provide a highly interactive learning experience for international healthcare professionals (HCPs) that care for patients with advanced NSCLC. To address this goal, the symposium will adopt a case-focused approach with the aim of aiding attendees in confirming their current practices and optimising their patient care.

To this aim, we would encourage you to use the audience response technology to foster dialogue between the Faculty and symposium attendees. Via this technology, attendees will be able to vote on which treatment decisions they would make during the interactive case studies. These decisions will be used to stimulate discussion about what is current best practice for advanced NSCLC patients.

The symposium will conclude with a Faculty panel discussion on the current and future best practice for individualised care. This will be a debate on the emerging therapies for the advanced and metastatic NSCLC patient and how clinicians can best operate within these new treatment paradigms and the resulting increased complexity in patient management. The therapy landscape for advanced NSCLC and, accordingly, the patient pathway through it, has greatly increased in complexity in recent years, so this discussion will provide a unique opportunity for attendees to discuss with the expert Faculty on how best to use the latest developments in therapy in their daily practice.

We would be grateful if you would kindly provide your feedback by completing the evaluation form provided to you at the symposium. This will enable us to tailor future programmes to your needs as a HCP treating patients with NSCLC.

Yours faithfully,

Pieter Postmus & Giorgio Scagliotti

Symposium Co-Chairs
Giorgio V. Scagliotti
Symposium Chair
Professor of Oncology,
University of Torino,
Torino, Italy

Dr Scagliotti is currently Professor of Oncology at the University of Torino. He earned his medical degree and completed his postgraduate training in Respiratory Medicine, Internal Medicine and Medical Oncology at the University of Torino. He is currently Chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino) and Head of the Department of Oncology at the University of Torino.

Dr Scagliotti is a member of several scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology (ASCO), and the International Association for the Study of Lung Cancer (IASLC). From 2003–2007 he was an Executive Board member of the IASLC. He is also Associate Editor for Journal of Thoracic Oncology, International Editor for Clinical Lung Cancer and the author or co-author of more than 280 publications in peer-reviewed journals. Alongside this, he is the International Editor of the 4th Edition of ‘Lung Cancer: Principles and Practice’ and co-editor of the IASCL textbook ‘Multidisciplinary Approach to Thoracic Oncology’.

Pieter E. Postmus
Symposium Chair
Professor of Thoracic Oncology,
Liverpool University,
Liverpool, UK

Professor Postmus was born in 1951 and obtained his MD at the University of Groningen in 1976. He trained as a pulmonologist in the University Hospital of Groningen from 1977–1981 and has worked in the field of thoracic oncology since 1978.

He defended his doctorate thesis “New approaches in small cell lung cancer” in 1985 and became Associate Professor in the Department of Pulmonary Diseases at the University Hospital of Groningen from 1989–1992.

Professor Postmus was Head Of Department and Professor of Pulmonary Diseases from 1992–2014 in Amsterdam. He was also a board member of the IASLC from 2003–2011 and President of the World Conference on Lung Cancer (WCLC) 2011, held in Amsterdam.

Since March 2015 he has been Professor of Thoracic Oncology in Liverpool. His research in thoracic oncology focuses on early detection, endobronchial therapy, staging procedures, testing and introducing new drugs and new combinations, and methods to communicate and inform patients and relatives.
Silvia Novello
Torino, Italy

Professor Novello graduated in Medicine from the University of Turino, Italy in 1995. She then did a Postgraduate Course in Respiratory Medicine. In 2006 she achieved a PhD in Human Oncology and went on to do a Postgraduate in Medical Oncology.

In the past she has worked at S. Luigi Hospital, Clinic of Respiratory Diseases, Turino; the Institut Gustave Roussy, Villejuif, France and the Thoracic Oncology Division, University of Turino. Now, she is Assistant Professor of Respiratory Medicine at the University of Turino, Department of Clinical and Biological Sciences, where her main area of expertise is based on the aspects of basic research and applied clinical research concerning bronchogenic carcinoma.

She has been involved in trials and studies in different lung cancer and pleural mesothelioma clinical stages including among others: supportive care, the treatment of lung cancer in elderly patients, the role of cytokines in thoracic malignancies (lung cancer, pleural mesothelioma), the role of oncogenes, anti-oncogenes, growth factors and their receptors in lung cancer (pathogenesis, prognosis), women and lung cancer, pharmacogenomics and lung cancer and applied clinical research aspects regarding interstitial lung disease.

Professor Novello is a Member of ASCO, Member of “Innovators in Lung Cancer” Member of IASLC and Board of Directors Member since July 2011, Member of NLCP (National Lung Cancer Partnership) Scientific Committee, Member of IASLC Young Young Investigators Awards Scientific Committee , BOD IASLC from 2011–2015 and President of the European Association - Women Against Lung Cancer in Europe (WALCE).

Fabrice Barlesi
Marseille, France

Fabrice Barlesi is Professor of Medicine and Head of the Multidisciplinary Oncology and Therapeutic Innovations department at Aix Marseille University, France. He also coordinates the Marseille's Early Phase Cancer Trials Centre dedicated to phase I trials in oncology. His main clinical interests in the field of lung cancer lie in angiogenesis, bioguided therapies and immuno-oncology (as a part of Marseille's Immunopole).

Erik Thunnissen
Amsterdam, Netherlands

Erik Thunnissen is consultant pathologist and staff member in the Department of Pathology, VUmc, Amsterdam, with a focus on Pulmonary Pathology. He is a long standing member of the IASLC pathology committee, leader of reproducibility studies of the WHO classification for lung cancer, and has taken responsibility for pulmonary molecular external quality assessment (EQA) programmes in the Netherlands and for the European Society of Pathology.
Symposium information

Organisers

This educational activity has been planned and independently implemented by Springer Healthcare IME.

Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Nature group.

Educational sponsorship

This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company.

Filming and photography

Springer Healthcare IME may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team your objection to this, your consent will be implied.
Advanced NSCLC: what are the options?

Congress Hall I & II
Friday 4 March 2016, 11:40 – 13:10

An independent satellite symposium held in conjunction with the 17th European Congress: Perspectives in Lung Cancer.

Prague, Czech Republic

– Biopsy to guide personalised treatment
– Optimal treatment for the specific patient: case studies
– Current and future best practice for individualised care

Lunch will be provided for all symposium attendees